Dana Whitfield I hope the expanded use leads to better access overall, though real-world results and side effect management will matter just as much as the trial numbers.
Tom Gallagher Curious how many insurers in Germany will actually cover this at launch, oral obesity meds still feel like they're priced for a niche market.
